These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1202 related articles for article (PubMed ID: 30219058)

  • 1. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
    Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
    Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
    Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
    Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly.
    Knüppel L; Ishikawa Y; Aichler M; Heinzelmann K; Hatz R; Behr J; Walch A; Bächinger HP; Eickelberg O; Staab-Weijnitz CA
    Am J Respir Cell Mol Biol; 2017 Jul; 57(1):77-90. PubMed ID: 28257580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
    Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
    Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report.
    Hagmeyer L; Treml M; Priegnitz C; Randerath WJ
    Respiration; 2016; 91(4):327-32. PubMed ID: 27073887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.
    Overed-Sayer C; Miranda E; Dunmore R; Liarte Marin E; Beloki L; Rassl D; Parfrey H; Carruthers A; Chahboub A; Koch S; Güler-Gane G; Kuziora M; Lewis A; Murray L; May R; Clarke D
    Thorax; 2020 Sep; 75(9):754-763. PubMed ID: 32709610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis.
    Lehtonen ST; Veijola A; Karvonen H; Lappi-Blanco E; Sormunen R; Korpela S; Zagai U; Sköld MC; Kaarteenaho R
    Respir Res; 2016 Feb; 17():14. PubMed ID: 26846335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis.
    Xie Y; Jiang H; Zhang Q; Mehrotra S; Abel PW; Toews ML; Wolff DW; Rennard S; Panettieri RA; Casale TB; Tu Y
    Respir Res; 2016 Aug; 17(1):103. PubMed ID: 27549302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATP-induced fibrogenic pathway in circulating cells obtained by idiopathic pulmonary fibrotic (IPF) patients is not blocked by nintedanib and pirfenidone.
    Colarusso C; Falanga A; Di Caprio S; Terlizzi M; D'Andria E; Antonio M; Maiolino P; Sorrentino R
    Biomed Pharmacother; 2024 Jul; 176():116896. PubMed ID: 38876049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.
    Epstein Shochet G; Wollin L; Shitrit D
    Respirology; 2018 Aug; 23(8):756-763. PubMed ID: 29532550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An ex vivo model to induce early fibrosis-like changes in human precision-cut lung slices.
    Alsafadi HN; Staab-Weijnitz CA; Lehmann M; Lindner M; Peschel B; Königshoff M; Wagner DE
    Am J Physiol Lung Cell Mol Physiol; 2017 Jun; 312(6):L896-L902. PubMed ID: 28314802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    George PM; Wells AU
    Expert Rev Clin Pharmacol; 2017 May; 10(5):483-491. PubMed ID: 28266906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs.
    Surolia R; Li FJ; Wang Z; Li H; Liu G; Zhou Y; Luckhardt T; Bae S; Liu RM; Rangarajan S; de Andrade J; Thannickal VJ; Antony VB
    JCI Insight; 2017 Jan; 2(2):e91377. PubMed ID: 28138565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells.
    Molina-Molina M; Machahua-Huamani C; Vicens-Zygmunt V; Llatjós R; Escobar I; Sala-Llinas E; Luburich-Hernaiz P; Dorca J; Montes-Worboys A
    BMC Pulm Med; 2018 Apr; 18(1):63. PubMed ID: 29703175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
    Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
    BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.
    Kamio K; Usuki J; Azuma A; Matsuda K; Ishii T; Inomata M; Hayashi H; Kokuho N; Fujita K; Saito Y; Miya T; Gemma A
    Pulm Pharmacol Ther; 2015 Jun; 32():29-36. PubMed ID: 25843005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
    Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
    BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.
    Moodley Y; Corte T; Richeldi L; King TE
    Respirology; 2015 Apr; 20(3):389-94. PubMed ID: 25727967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
    Takehara K; Koga Y; Hachisu Y; Utsugi M; Sawada Y; Saito Y; Yoshimi S; Yatomi M; Shin Y; Wakamatsu I; Umetsu K; Kouno S; Nakagawa J; Sunaga N; Maeno T; Hisada T
    Cells; 2022 Jan; 11(1):. PubMed ID: 35011705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of pirfenidone in a sheep model of pulmonary fibrosis.
    Dewage SNV; Organ L; Koumoundouros E; Derseh HB; Perera KUE; Samuel CS; Stent AW; Snibson KJ
    Exp Lung Res; 2019; 45(9-10):310-322. PubMed ID: 31762329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.